Ovid Therapeutics Inc. (OVID) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 16 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026before open 41 8-K
Q4 FY2025Wed, Mar 18, 2026before open 77 8-K
Q3 FY2025Wed, Nov 12, 2025before open 43 8-K
Q1 FY2025Tue, May 13, 2025before open 43 8-K
Q4 FY2024Tue, Mar 11, 2025before open 70 8-K
Q1 FY2024Tue, May 14, 2024before open 44 8-K
Q4 FY2023Fri, Mar 8, 2024before open 68 8-K
Q3 FY2023Fri, Nov 3, 2023before open 34 8-K

What they guided beta

Q3 FY2026 "OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027" exhibit
Q3 FY2026 "Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027" exhibit
Q3 FY2026 "Cash, cash equivalents and marketable securities were $161.4 million as of September 30, 2026; expected financial runway into 2029 NEW YORK, November 10, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026." exhibit
Q3 FY2026 "“We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor." exhibit
Q3 FY2026 "The study is enrolling, and Ovid anticipates reading out topline data in the first quarter of 2027." exhibit
Q4 FY2025 "$90.4 million in cash, cash equivalents and marketable securities as of December 31, 2025, expected to fund key studies for OV329 and OV4071 and operations into late 2028; exercise of outstanding warrants may further extend runway into 2029" exhibit
Q4 FY2025 "Ovid is engaged in regulatory conversations and currently anticipates initiating the Phase 2 study in the second quarter of 2026." exhibit
Q4 FY2025 "The Company will be hosting an R&D Day dedicated to the KCC2 portfolio on April 14, 2026." exhibit
Q4 FY2025 "If all Series A Warrants are exercised in full, the Company anticipates receiving up to an additional $53.9 million in gross proceeds, prior to deducting placement agent fees, potentially extending Ovid’s cash runway into 2029." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/OVID
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/OVID

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

OVID earnings date badge

HTML

<a href="https://veritasdata.dev/company/OVID/"><img src="https://veritasdata.dev/embed/OVID.svg" alt="OVID earnings date" width="240" height="56"></a>

Markdown

[![OVID earnings date](https://veritasdata.dev/embed/OVID.svg)](https://veritasdata.dev/company/OVID/)

Script

<script async src="https://veritasdata.dev/embed/OVID.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/OVID"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.